A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes ...

Intellia Therapeutics Inc (($NTLA)) has held its Q4 earnings call. Read on for the main highlights of the call. Intellia Therapeutics’ Earnings ...

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

IB-T101 demonstrated superior preclinical efficacy in an aggressive renal cell tumor model, significantly outperforming ...

Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...